Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF +2.57%49 3-Year EPS without NRI Growth Rate is 41.00% as of Dec. 2025, which is 26% above its 10-year median of 32.50. GuruFocus rates ABDXF with a GF Scoreâ„¢ of 49/100 and a GF Valueâ„¢ of $0.21 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 157 Medical Diagnostics & Research companies, Abingdon Health ranks better than 77.07% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 41.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Abingdon Health was 41.00% per year. The lowest was -37.80% per year. And the median was 32.50% per year.
Abingdon Health (OTCPK:ABDXF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Abingdon Health 3-Year EPS without NRI Growth Rate Related Terms
ABDXF vs TMO, DHR, IDXX: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Abingdon Health's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Abingdon Health's 3-Year EPS without NRI Growth Rate falls into.
Abingdon Health 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 41.00% mean?
Abingdon Health (ABDXF) has a 3-Year EPS without NRI Growth Rate of 41.00% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Abingdon Health and its competitors. This is 26% above median its historical median of 32.50. According to the industry distribution chart, Abingdon Health ranks #36 out of 157 companies in the Medical Diagnostics & Research industry, placing it in the top 22.9%.
Is Abingdon Health's 3-Year EPS without NRI Growth Rate too high?
Abingdon Health's current 3-Year EPS without NRI Growth Rate of 41.00% is 26% above median its 10-year median of 32.50. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.70. Abingdon Health's value of 41.00% is 283.2% above this industry median. Based on the distribution chart, Abingdon Health ranks #36 out of 157 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #36 out of 157 companies for 3-Year EPS without NRI Growth Rate. This places Abingdon Health in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 10.70. Abingdon Health's value of 41.00% is 283.2% above this benchmark. While the company's 10-year median is 32.50 vs. the industry median of 10.70, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.70, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current 3-Year EPS without NRI Growth Rate of 41.00% is 283.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current 3-Year EPS without NRI Growth Rate is 41.00%, which is 26% above median its own 10-year median of 32.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 31.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 41.00%, which is 26% above median its 10-year median of 32.50 and 283.2% above the Medical Diagnostics & Research industry median of 10.70. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current 3-Year EPS without NRI Growth Rate is 41.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 31.6% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
3-Year EPS without NRI Growth Rate: 41.00% (26% above median its 10-year median of 32.50)
GF Value™: $0.21 vs. price of $0.14 (31.6% below fair value)
Industry Position: 283.2% above the Medical Diagnostics & Research median (#36 of 157)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
